An in vivo model of met-driven lymphoma as a tool to explore the therapeutic potential of met inhibitors

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2220-2226

  Accornero, Paolo ^a   Lattanzio, Giuseppe ^a   Mangano, Tony ^a   Chiarle, Roberto ^a   Taulli, Riccardo ^a   Bersani, Francesca ^a   Forni, Paolo E ^a   Miretti, Silvia ^a   Scuoppo, Claudio ^a,c   Dastrù, Walter ^a   Christensen, James G ^b   Crepaldi, Tiziana ^a   Ponzetto, Carola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b PFIZER INC   (United States)

^c Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; SCATTER FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; TETRATRICOPEPTIDE REPEAT;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; LYMPHOMA; MICE; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SULFONES;

EID: 42249110570     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2064     Document Type: Article

References (30)

1. Varmus H. The new era in cancer research. Science 2006;312:1162-5.
2. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8.
3. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
4. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
6. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
8. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
9. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
10. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
11. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
12. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
13. Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153:1023-34.
14. Graveel C, Su Y, Koeman J, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci U S A 2004;101:17198-203.
15. Otsuka T, Takayama H, Sharp R, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 1998;58:5157-67.
16. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8:1276-80.
17. Takayama H, Larochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997;94:701-6.
18. Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res 2002;62:6724-30.
19. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 1996;97:2872-7.
20. Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007;26:1276-85.
21. Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol 1993;13:6711-22.
22. Crepaldi T, Bersani F, Scuoppo C, et al. Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem 2007;282:6812-22.
23. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
24. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003;101:1919-27.
25. Tjin EP, Groen RW, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;107:760-8.
26. Tamura S, Sugawara T, Tokoro Y, et al. Expression and function of c-Met, a receptor for hepatocyte growth factor, during T-cell development. Scand J Immunol 1998;47:296-301.
27. Runge DM, Runge D, Foth H, Strom SC, Michalopoulos GK. STAT 1α/1β, STAT 3 and STAT 5: expression and association with c-MET and EGF-receptor in long-term cultures of human hepatocytes. Biochem Biophys Res Commun 1999;265:376-81.
28. Kelly JA, Spolski R, Kovanen PE, et al. Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J Exp Med 2003;198:79-89.
29. Choi YL, Tsukasaki K, O'Neill MC, et al. A genomic analysis of adult T-cell leukemia. Oncogene 2007;26:1245-55.
30. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiprolifer-ative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17.